Biotechnology Sector Expected to Experience Increased Investment in Neurodevelopmental Disorder Therapies Over the Next 5-10 Years, Driven by New Insights into Genetic Vulnerabilities and Treatment Strategies for Autism Spectrum Disorder.
ABBVCRSPEDITJNJNTLAPFE
Statements (2)
- Bullish
Pharmaceutical Companies Developing ASD Treatments Will Likely See Increased Investment In innovative therapies utilizing non-mammalian model systems over the next 5-10 years Due To the abstract's findings on the identification of common biological pathways and pharmacological targets for autism spectrum disorder (ASD) using scalable non-mammalian systems.
- Bullish
The Biotechnology Sector Will Likely See Increased Investment In companies developing therapies targeting synaptic plasticity in the coming years Due To the abstract's findings on the role of the eIF4E gene in autism spectrum disorder, suggesting new avenues for treatment development.